Abstract: Provided a liquid crystal composition including ceramide, a method of preparing the same, and a cosmetic composition including the same. According to a liquid crystal composition including various types of ceramide of an aspect and a method of preparing the same, the liquid crystal composition not only has high liquid crystal stability that liquid crystal is maintained even after 4 weeks at a high temperature, but also activities of increasing an amount of ceramide, increasing an expression level of aquaporin 3, increasing an amount of filaggrin, increasing an expression level of hyaluronic acid, increasing an expression level of loricrin, increasing an expression level of involucrin, and increasing a thickness of the skin, resulting in effects usefully available for amelioration of the skin conditions.

Abstract: Methods of treating a cancer or a tumor in a subject using a composition are provided. The composition includes a therapeutically effective amount of 2,4-disulfonyl a-phenyl tert-butyl nitrone (2,4-ds-PBN) or pharmaceutically acceptable salts thereof, wherein the therapeutically effective amount decreases a growth of the cancer or the tumor.

Abstract: A method of treating or preventing pruritus in a subject in need thereof using a pharmaceutical composition is provided. The method includes administering a therapeutically effective amount of T?4, T?4 fragments, T?4 isoforms, T?4 derivatives, or variants thereof, wherein the therapeutically effective amount decreases release of a pruritus-related factor or decreases release of an inflammatory cytokine from a target tissue is provided.

Abstract: The present invention relates to a method for manufacturing an ophthalmic preparation comprising thymosin ?4. According to the inventive method, the manufacture of an ophthalmic preparation comprising thymosin ?4 is carried out in the presence of an inert gas, thus the contact of thymosin ?4 with oxygen is blocked and the oxidation of thymosin ?4 can be prevented and the pharmacological activity of thymosin ?4 maintains for long-term period. Therefore, the ophthalmic preparation prepared by the inventive method can maintain the pharmacological activity of thymosin ?4 in a stable state for a long time.

Abstract: The present invention relates to a therapeutic agent for ophthalmic disease containing thymosin beta 4. The present invention is more effective in reducing xerophthalmia than an ophthalmic solution containing cyclosporine A, is less irritant to eyes than conventional ophthalmic solutions and is physiochemically safe.

Abstract: The present invention relates to a method for manufacturing an ophthalmic preparation comprising thymosin ?4. According to the inventive method, the manufacture of an ophthalmic preparation comprising thymosin ?4 is carried out in the presence of an inert gas, thus the contact of thymosin ?4 with oxygen is blocked and the oxidation of thymosin ?4 can be prevented and the pharmacological activity of thymosin ?4 maintains for long-term period. Therefore, the ophthalmic preparation prepared by the inventive method can maintain the pharmacological activity of thymosin ?4 in a stable state for a long time.

Abstract: The present invention relates to a composition for the treatment or prevention of a corneal injury, which comprises thymosin ?4, and citric acid or its salt as active ingredients. The composition may further comprise at least one organic acid selected from acetic acid, ascorbic acid or salts thereof. The composition can maintain or increase the activity of thymosin ?4 conventionally used to effectively treat wounds on the cornea, and thus, is useful as an ophthalmic formulation for treating the corneal injury.

Abstract: The present invention relates to a therapeutic agent for ophthalmic disease containing thymosin beta 4. The present invention is more effective in reducing xerophthalmia than an ophthalmic solution containing cyclosporine A, is less irritant to eyes than conventional ophthalmic solutions and is physiochemically safe.

Abstract: The present invention relates to a composition for the treatment or prevention of a corneal injury, which comprises thymosin ?4, and citric acid or its salt as active ingredients. The composition may further comprise at least one organic acid selected from acetic acid, ascorbic acid or salts thereof. The composition can maintain or increase the activity of thymosin ?4 conventionally used to effectively treat wounds on the cornea, and thus, is useful as an ophthalmic formulation for treating the corneal injury.